MONOGRAM BIOSCIENCES, INC. - HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES.
Key Details
Description
HIGH THROUGHPUT SARS-COV-2 NEUTRALIZING ANTIBODY IMMUNOASSAY FOR QUALIFYING VARIANTS AND TESTING OF HUMAN SERUM SAMPLES.
Context & Analysis
On Mar 4, 2026, Department of Health and Human Services obligated $38,008,678.5 to MONOGRAM BIOSCIENCES, INC. for high throughput sars-cov-2 neutralizing antibody immunoassay for qualifying variants and testing of human serum samples.. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: not competed with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in SOUTH SAN FRANCISCO, CA. The contract is scheduled through Sep 30, 2029. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.